Targeted Medical Pharma Combats the Epidemic of Pain with Release of THERALEVE™

Los Angeles, — Targeted Medical Pharma, Inc. (OTCQB: TRGM) in conjunction with Amino Nutritionals LLC, today announced the consumer release of THERALEVE™ (www.theralevehealth.com) a patented amino acid based formula designed by pain management physicians to help the 100 million chronic pain sufferers in the United States, fight pain and inflammation without the dangerous side effects commonly associated with NSAIDs and opioids. “Common pain medications do not address the nutritional needs of the nervous system and only target symptoms of pain. THERALEVE provides a specific blend Continue reading →

Targeted Medical Pharma Finalizes Exclusive Agreement for Distribution in CHINA

Los Angeles – Targeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product licensing agreement with Healthy Focus Limited, a Hong Kong based company that specializes in distributing healthcare products throughout China. The Agreement grants Healthy Focus an exclusive three-year renewable license for the marketing and sale of Theramine®, Percura™ and Trepadone® in Hong Kong and China. Under the terms of the Agreement, Healthy Focus is responsible for registering all products in China, an initial licensing fee as well as maintaining annual Continue reading →

TARGETED MEDICAL PHARMA BREAKS GROUND IN THE CONSUMER GOODS MARKET

Targeted Medical Pharma, Inc. (OTCQB: TRGM), announced the establishment of a new subsidiary, Amino Nutritionals LLC, that will specialize in the development and marketing of THERALEVE™, a proprietary consumer product for chronic pain sufferers to be sold in the United States and abroad. The Company is pleased to announce the hiring of Joshua Levine as the Vice President of Direct Consumer Sales. Mr. Levine will spearhead the direct marketing efforts for Amino Nutritionals, and will be responsible for building the infrastructure required for market development Continue reading →

Research Identifies a Potential New Path to Developing a Treatment for Chronic Pain

Los Angeles, September 8, 2015 – Targeted Medical Pharma to present new chronic pain research that reveals significant nervous system abnormalities among patients suffering from Fibromyalgia, at the 2015 PainWeek national conference in Las Vegas, Nevada. The study looked at 329 Fibromyalgia patients and 58 control patients all of whom wore Holter monitors for a 24 hour period to measure nervous system activity. The results of this study showed that patients with Fibromyalgia experience a significant decrease in both nighttime parasympathetic nervous system (PNS) activity and daytime sympathetic Continue reading →

New Research Finds a Link Between Obesity and Nutritional Deficiencies

Los Angeles, CA, April 27, 2015 — Obesity has reached epidemic proportions affecting nearly 78 million adults in the United States and has been linked with an increased risk of diabetes, heart disease, and cancer. Recent studies have suggested that obese patients have specific amino acid deficiencies that can contribute to obesity. The latest research report entitled “Nutritional Deficiencies Associated with Obesity,” published online in the Journal of Obesity and Weight Loss Therapy, highlights the specific amino acid and nutrient deficiencies that are commonly associated Continue reading →

Targeted Medical Pharma Announces New Partnership for Exclusive Distribution in Japan

Los Angeles, February 19,  2015 – Targeted Medical Pharma (OTCQB: TRGM), today announced the completion of an exclusive product distribution agreement with J-Network Inc., a  California-based company that specializes in distributing cosmetic and healthcare goods exclusively to Japan. The Agreement grants J-Network an exclusive one-year renewable license for the marketing and sales of the Company’s proprietary product, designed to improve sleep and immune function, in Japan. Under the terms of the Agreement, Targeted Medical Pharma will develop new products specific for import into the Japanese Continue reading →

Targeted Medical Pharma Announces Changes in Management and Board of Directors

New Management Structure Positions Company for Growth and Profitability Los Angeles, CA, January 29, 2015 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced several major changes that streamline operations and signify a commitment to revenue growth, cost containment and profitability. The Company has appointed Kim Giffoni, a co-founder and former Vice President of Foreign Sales at Targeted Medical Pharma, as the Chief Executive Officer. Dr. David Silver, former Chief Operating Officer and President at the Company, has been appointed Chief Medical Officer, and Marcus Continue reading →

Targeted Medical Pharma, Inc. Announces Q3 Financial Results and Clinical Program Updates

Los Angeles, CA, November 18, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development biotechnology company, today announced financial results for its third quarter ended September 30, 2014 and clinical trial updates. The company reported significant improvement in both net loss and net loss before interest, taxes, depreciation and amortization, and stock based compensation (Adjusted EBITDA*) on a quarter-over-quarter basis. In Addition, in Q3, the company reported major advances in the development of new treatments for both chronic low back pain Continue reading →

Targeted Medical Pharma Releases Promising Trial Results for the Treatment of Posttraumatic Stress Disorder

Study Shows Medical Foods Sentra AM and Sentra PM Effective at Reducing Symptoms of PTSD in Veterans Los Angeles, CA, October  13, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM) a drug discovery and development company, today announced the results of a clinical trial studying the amino acid based medical foods, Sentra AM and Sentra PM in Veterans suffering from symptoms associated with Posttraumatic Stress Disorder (PTSD). In this 30 day open label pilot study (n=21), published in the Journal of Central Nervous System Disease, Continue reading →

Targeted Medical Pharma’s New Approach to Pain Management Targets Epidemic of Opioid and NSAID Over-Prescribing

White Paper explores Theramine® as a Safe and Clinically Effective Alternative to Common Pain Medications  Los Angeles, CA, October 6, 2014 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), recently published the White Paper: Innovations in Pain Management discussing the epidemic of pain, the dangers of commonly prescribed pain medications and the benefits of Theramine, as a clinically effective alternative to opioids and nonsteroidal anti-inflammatory (NSAID) drugs for the management of back pain and inflammation. According to Consumer Reports, the overuse of opioid pain medications has reached epidemic Continue reading →